Tirzepatide A dual agonist (GLP-1 + GIP)
Cagrilintidesemaglutide in adults with overweight or obesity and type 2 diabetes (Redefine 2 trial) Summary: This Phase 3a, double-blind, randomized, placebo-controlled trial investigated the efficacy and safety of once-weekly subcutaneous cagrilintidesemaglutide (2.4 mg each) in adults with a BMI of 27 or more and type 2 diabetes
Thyroid considerations: ~6.5% of patients developed subclinical hypothyroidism in one study [5]
Moreover, abnormalities associated with hypertension, such as insulin resistance and hyperlipidemia (high lipid levels), can be worsened by some anti-hypertensive medications
Key Benefits: This synergistic peptide duo is a top choice for growth hormone optimization
For instance, if you're administering 1ml injections twice weekly, a 10ml vial will suffice for 5 weeks, while a 30ml vial will last you 15 weeks